Shares of Natera, Inc. (NASDAQ:NTRA) have earned an average recommendation of “Hold” from the eight ratings firms that are covering the firm, Marketbeat Ratings reports. Four research analysts have rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $15.75.
Several research firms have recently commented on NTRA. Zacks Investment Research downgraded Natera from a “buy” rating to a “sell” rating in a report on Saturday. ValuEngine raised Natera from a “strong sell” rating to a “sell” rating in a report on Thursday. Canaccord Genuity increased their price objective on Natera from $14.00 to $16.00 and gave the company a “buy” rating in a report on Wednesday, May 10th. BidaskClub downgraded Natera from a “buy” rating to a “hold” rating in a report on Tuesday, July 25th. Finally, Morgan Stanley cut their price objective on Natera from $18.00 to $13.00 and set an “overweight” rating for the company in a report on Monday, August 7th.
Natera (NTRA) opened at 10.62 on Friday. The company’s market cap is $565.07 million. The stock has a 50 day moving average of $9.97 and a 200-day moving average of $9.55. Natera has a 52-week low of $7.35 and a 52-week high of $12.95.
Natera (NASDAQ:NTRA) last released its quarterly earnings data on Tuesday, August 8th. The medical research company reported ($0.52) EPS for the quarter, meeting the consensus estimate of ($0.52). The company had revenue of $53.60 million during the quarter, compared to the consensus estimate of $50.57 million. Natera had a negative return on equity of 119.47% and a negative net margin of 62.64%. The firm’s revenue for the quarter was up 3.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.46) EPS. On average, analysts forecast that Natera will post ($2.08) EPS for the current year.
Large investors have recently bought and sold shares of the stock. Virtu KCG Holdings LLC acquired a new stake in Natera during the second quarter worth $126,000. Vanguard Group Inc. boosted its stake in Natera by 12.6% in the second quarter. Vanguard Group Inc. now owns 2,261,052 shares of the medical research company’s stock worth $24,555,000 after buying an additional 253,344 shares during the period. Northern Trust Corp boosted its stake in Natera by 21.0% in the second quarter. Northern Trust Corp now owns 352,808 shares of the medical research company’s stock worth $3,831,000 after buying an additional 61,226 shares during the period. New York State Common Retirement Fund boosted its stake in Natera by 31.1% in the second quarter. New York State Common Retirement Fund now owns 35,400 shares of the medical research company’s stock worth $384,000 after buying an additional 8,399 shares during the period. Finally, TIAA CREF Investment Management LLC boosted its stake in Natera by 31.6% in the second quarter. TIAA CREF Investment Management LLC now owns 123,534 shares of the medical research company’s stock worth $1,342,000 after buying an additional 29,633 shares during the period. Institutional investors and hedge funds own 59.74% of the company’s stock.
WARNING: This piece was first reported by Community Financial News and is owned by of Community Financial News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.com-unik.info/2017/08/12/brokerages-set-natera-inc-ntra-price-target-at-17-50-updated-updated-updated.html.
Natera Company Profile
What are top analysts saying about Natera Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Natera Inc. and related companies.